Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the early chronic GvHD events (first line therapy), if the
addition of arsenic trioxide to standard therapy with corticosteroids, with or without
cyclosporine, will be effective in controlling chronic GvHD and to reduce the duration of
corticosteroid therapy